DOR BioPharma Inc. said a buyout offer by Cell Therapeutics Inc. cannot be considered at this time due to the company's letter of intent with a potential partner for its lead program orBec, a corticosteroid pending regulatory approval in gastrointestinal graft-vs.-host disease. (BioWorld Today) Read More
